Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Why It Matters

Employer and payer pushback threatens the revenue trajectory of high‑priced obesity therapies and accelerates a shift toward cash‑pay models, reshaping the pharmaceutical market and patient access.

Key Takeaways

• 49% of firms refuse to cover GLP‑1s for obesity at any price
• 90% of large plans worry about GLP‑1 affordability
• Cigna ends weight‑loss GLP‑1 coverage for employees effective July 1
• Employers steer workers to cash‑pay market, $150/month average price
• Two‑thirds of non‑diabetic patients discontinue GLP‑1s within a year

Pulse Analysis

GLP‑1 agonists such as Ozempic, Wegovy and the newer Zepbound have reshaped obesity treatment in the United States, delivering clinically significant weight loss that many insurers once deemed experimental. Their rapid adoption, however, has been tempered by list prices that can exceed $1,000 per month for injectable formulations, prompting patients and employers to hunt for lower‑cost alternatives. In the past year, the cash‑pay market has softened, with oral and injectable versions now averaging roughly $150 a month, a price point that still strains large benefit budgets but is markedly cheaper than brand‑list rates.

A new Pharmaceutical Strategies Group survey of 235 benefits executives reveals a growing backlash. Nearly half of firms that currently do not cover GLP‑1s for obesity say they would never do so, and 90 % of plans with a median enrollment of 14,000 express moderate to high concern over drug affordability. Cigna’s July 1 decision to drop weight‑loss coverage for its employees mirrors the 95 % of employers that continue to cover GLP‑1s only for type‑2 diabetes. High discontinuation—two‑thirds of non‑diabetic users stop within a year—feeds skepticism, pushing employers toward cash‑pay programs and broader weight‑management resources.

For pharmaceutical manufacturers, the shift signals a need to rethink pricing and outcomes strategies. Value‑based contracts that tie reimbursement to sustained weight loss or glycemic control could mitigate payer resistance, while expanding indications for diabetes may preserve a revenue stream. Meanwhile, patients left without formulary support may face out‑of‑pocket costs that limit adherence, potentially eroding the long‑term health gains that justified the drugs’ premium pricing. The industry’s response will shape the next phase of obesity therapeutics and determine whether GLP‑1s remain a cornerstone of employer‑sponsored health benefits.